In the phase 3 PROSPECT trial, patients with locally advanced rectal cancer had similar outcomes if they received pelvic chemoradiation or if they received FOLFOX with chemoradiation added only in select cases.
Zanidatamab can produce rapid and durable responses in patients with advanced HER2-positive biliary tract cancer, phase 2 data suggest.
Treatment with tucatinib and trastuzumab elicits responses in previously treated, HER2-positive metastatic biliary tract cancer.
Adding nivolumab to adjuvant chemotherapy did not improve relapse-free survival in a phase 3 trial of patients with gastric/GEJ cancer.
NALIRIFOX can improve survival vs gemcitabine plus nab-paclitaxel in patients with previously untreated, metastatic pancreatic ductal adenocarcinoma, a phase 3 trial suggests.
Neoadjuvant FOLFIRINOX does not provide a survival benefit over upfront surgery in resectable pancreatic cancer, a phase 2 study suggests.
Palliative care does not improve health-related quality of life among patients undergoing curative-intent surgery for upper gastrointestinal cancer, a study suggests.
Abdominal pain, rectal bleeding, diarrhea, and iron deficiency anemia were associated with early-onset CRC.
In metastatic esophageal/gastroesophageal junction cancer, the addition of cixutumumab to paclitaxel does not improve outcomes vs paclitaxel alone.
Cancer death rates in the US have declined in recent years, but the declines vary by congressional district, a study suggests.
